Switzerland’s Labatec Pharma SA (Labatec) is the latest firm to get its hands on Futura Medical plc’s game changing erectile dysfunction (ED) treatment MED3000 in a deal that promises to take the drug-free gel to the Middle East.
Under the terms of the agreement, which is for an initial eight-year period, Futura and Labatec will work together to gain marketing authorization and commercialize MED3000 as a clinically proven treatment for ED in Jordan, Lebanon, Iraq and the GCC region of
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?